Heart Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Heart transplantation is the therapy used in various heart diseases. Heart transplant replaces an injured or diseased heart with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted heart as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.
The Heart Transplant Rejection pipeline drugs market research report provides comprehensive information on the therapeutics under development for Heart Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Heart Transplant Rejection and features dormant and discontinued projects.
Heart Transplant Rejection Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Heart Transplant Rejection pipeline drugs market are Janus Kinase, CD40 Ligand, Protein Kinase C Theta Type, T Cell Specific Surface Glycoprotein CD28, Tumor Necrosis Factor Receptor Superfamily Member 5, and V Type Proton ATPase 116 Kda Subunit A Isoform 3. Janus Kinase leads this segment of the Heart Transplant Rejection pipeline drugs market.
Heart Transplant Rejection Pipeline Drugs Market Analysis, by Targets
For more Heart Transplant Rejection pipeline drugs market target insights, download a free report sample
Heart Transplant Rejection Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the Heart Transplant Rejection pipeline drugs market are Janus Kinase Inhibitor, CD40 Ligand Inhibitor, Protein Kinase C Theta Type Inhibitor, T Cell Specific Surface Glycoprotein CD28 Antagonist, Tumor Necrosis Factor Receptor Superfamily Member 5 Antagonist, and V Type Proton ATPase 116 Kda Subunit A Isoform 3 Inhibitor. Janus Kinase Inhibitor leads the Heart Transplant Rejection pipeline drugs market in terms of MoA.
Heart Transplant Rejection Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanisms of action insights into the Heart Transplant Rejection pipeline drugs market, download a free report sample
Heart Transplant Rejection Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Heart Transplant Rejection pipeline drugs market are intravenous, parenteral, and subcutaneous. Intravenous leads the Heart Transplant Rejection pipeline drugs market in terms of RoA.
Heart Transplant Rejection Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Heart Transplant Rejection pipeline drugs market, download a free report sample
Heart Transplant Rejection Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Heart Transplant Rejection pipeline drugs market are monoclonal antibody, small molecule, cell therapy, and fusion protein. Monoclonal Antibody leads the Heart Transplant Rejection pipeline drugs market in terms of molecule types.
Heart Transplant Rejection Pipeline Drugs Market Analysis, by Molecule Types
For more molecule-type insights into the Heart Transplant Rejection pipeline drugs market, download a free report sample
Heart Transplant Rejection Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the Heart Transplant Rejection pipeline drugs market are Astellas Pharma Inc, Bristol-Myers Squibb Co, Kiniksa Pharmaceuticals Ltd, Nekonal Sarl, and Tonix Pharmaceuticals Holding Corp. Astellas Pharma Inc has the highest number of products under development.
Heart Transplant Rejection Pipeline Drugs Market Analysis, by Companies
To know more about the Heart Transplant Rejection pipeline drugs market companies, download a free report sample
Heart Transplant Rejection Pipeline Drugs Market Report Overview
Key Targets | Janus Kinase, CD40 Ligand, Protein Kinase C Theta Type, T Cell Specific Surface Glycoprotein CD28, Tumor Necrosis Factor Receptor Superfamily Member 5, and V Type Proton ATPase 116 Kda Subunit A Isoform 3 |
Key Mechanisms of Action | Janus Kinase Inhibitor, CD40 Ligand Inhibitor, Protein Kinase C Theta Type Inhibitor, T Cell Specific Surface Glycoprotein CD28 Antagonist, Tumor Necrosis Factor Receptor Superfamily Member 5 Antagonist, and V Type Proton ATPase 116 Kda Subunit A Isoform 3 Inhibitor |
Key Routes of Administration | Intravenous, Parenteral, and Subcutaneous |
Key Molecule Types | Monoclonal Antibody, Small Molecule, Cell Therapy, and Fusion Protein |
Key Companies | Astellas Pharma Inc, Bristol-Myers Squibb Co, Kiniksa Pharmaceuticals Ltd, Nekonal Sarl, and Tonix Pharmaceuticals Holding Corp |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Heart Transplant Rejection.
- The pipeline guide reviews pipeline therapeutics for Heart Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Heart Transplant Rejection therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Heart Transplant Rejection therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Heart Transplant Rejection
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Heart Transplant Rejection.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Heart Transplant Rejection pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Bristol-Myers Squibb Co
Kiniksa Pharmaceuticals Ltd
Nekonal Sarl
Tonix Pharmaceuticals Holding Corp
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Heart Transplant Rejection pipeline drugs market?
Some of the targets of the Heart Transplant Rejection pipeline drugs market are Janus Kinase, CD40 Ligand, Protein Kinase C Theta Type, T Cell Specific Surface Glycoprotein CD28, Tumor Necrosis Factor Receptor Superfamily Member 5, and V Type Proton ATPase 116 Kda Subunit A Isoform 3.
-
What are the key mechanisms of action in the Heart Transplant Rejection pipeline drugs market?
Some of the mechanisms of action of the Heart Transplant Rejection pipeline drugs market are Janus Kinase Inhibitor, CD40 Ligand Inhibitor, Protein Kinase C Theta Type Inhibitor, T Cell Specific Surface Glycoprotein CD28 Antagonist, Tumor Necrosis Factor Receptor Superfamily Member 5 Antagonist, and V Type Proton ATPase 116 Kda Subunit A Isoform 3 Inhibitor.
-
What are the key routes of administration in the Heart Transplant Rejection pipeline drugs market?
The key routes of administration in the Heart Transplant Rejection pipeline drugs market are intravenous, parenteral, and subcutaneous.
-
What are the key molecule types in the Heart Transplant Rejection pipeline drugs market?
The molecule types in the Heart Transplant Rejection pipeline drugs market are monoclonal antibody, small molecule, cell therapy, and fusion protein.
-
Which are the leading companies in the Heart Transplant Rejection pipeline drugs market?
Some of the leading companies in the Heart Transplant Rejection pipeline drugs market are Astellas Pharma Inc, Bristol-Myers Squibb Co, Kiniksa Pharmaceuticals Ltd, Nekonal Sarl, and Tonix Pharmaceuticals Holding Corp.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.